logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12742161 B1

PDFFull Text
Date of Patent:
Sep. 22, 2026

Filed:

Sep. 22, 2021

Inactive telomerase, adenovirus associated virus and artificial mrna having same and use thereof

Applicants:

Zhejiang Juvensis Therapeutics Co., Ltd., Taizhou, CN;

Nanjing Juvensis Therapeutics Co., Ltd., Nanjing, CN;

Inventors:

Jiahao Zhang, Nanjing, CN;

Xue Zeng, Taizhou, CN;

Assignees:

Zhejiang Juvensis Therapeutics Co., Ltd., Taizhou, CN;

Nanjing Juvensis Therapuetics Co., Ltd., Nanjing, CN;

Attorney:

Stinson LLP

Primary Examiner:

Richard G Hutson

Int. Cl.
CPC ...
C12N 9/12 (2006.01); A61K 48/00 (2006.01); A61P 9/00 (2006.01); C12N 7/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/1276 (2013.01); A61K 48/005 (2013.01); A61P 9/00 (2018.01); C12N 7/00 (2013.01); C12Y 207/07049 (2013.01); A61K 38/00 (2013.01); C12N 2750/14122 (2013.01);
Abstract

The present invention discloses an inactive telomerase, which is a double mutant telomerase having double mutation sites Y707F and D868A. The present invention also discloses an adenovirus-inactive telomerase and an artificial mRNA-inactive telomerase having double mutation sites, and use thereof in the treatment of diseases associated with non-dividing cell telomere shortening. The present invention is capable of inhibiting the activity of telomerase TERT in non-dividing cells to form an inactive telomerase CI-TERT and simultaneously preventing the telomerase from leaving the nucleus. By such configuration, the telomerase can be kept in the nucleus to protect the telomeric ends from shortening and prevent telomerase from causing telomere lengthening to the extent of cell carcinogenesis, thus reducing the risk of carcinogenesis and keeping the telomerase in the nucleus to protect the telomeric ends and inhibiting the deterioration of the disease caused by telomere shortening.

Find Patent Forward Citations

Quick Actions:

Zhang, Jiahao. (2026). Inactive telomerase, adenovirus associated virus and artificial mrna having same and use thereof (U.S. Patent No. 12742161). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12742161

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…